Literature DB >> 26478203

Report on the second WHO integrated meeting on development and clinical trials of influenza vaccines that induce broadly protective and long-lasting immune responses: Geneva, Switzerland, 5-7 May 2014.

Nancy J Cox1, Julian Hickling2, Rebecca Jones2, Guus F Rimmelzwaan3, Linda C Lambert4, John Boslego5, Larisa Rudenko6, Leena Yeolekar7, James S Robertson8, Joachim Hombach9, Justin R Ortiz9.   

Abstract

On 5-7 May 2014, the World Health Organization (WHO) convened the second integrated meeting on "influenza vaccines that induce broadly protective and long-lasting immune responses". Around 100 invited experts from academia, the vaccine industry, research and development funders, and regulatory and public health agencies attended the meeting. Areas covered included mechanisms of protection in natural influenza-virus infection and vaccine-induced immunity, new approaches to influenza-vaccine design and production, and novel routes of vaccine administration. A timely focus was on how this knowledge could be applied to both seasonal influenza and emerging viruses with pandemic potential such as influenza A (H7N9), currently circulating in China. Special attention was given to the development of possible universal influenza vaccines, given that the Global Vaccine Action Plan calls for at least one licensed universal influenza vaccine by 2020. This report highlights some of the topics discussed and provides an update on studies published since the report of the previous meeting.
Copyright © 2015. Published by Elsevier Ltd.. All rights reserved.

Entities:  

Keywords:  H7N9 vaccine; Influenza; Pandemic influenza vaccine; Seasonal influenza vaccine; Universal influenza vaccine; Vaccine

Mesh:

Substances:

Year:  2015        PMID: 26478203      PMCID: PMC8218335          DOI: 10.1016/j.vaccine.2015.10.014

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  59 in total

1.  Protective efficacy of a trivalent recombinant hemagglutinin protein vaccine (FluBlok®) against influenza in healthy adults: a randomized, placebo-controlled trial.

Authors:  John J Treanor; Hana El Sahly; James King; Irene Graham; Ruvim Izikson; Robert Kohberger; Peter Patriarca; Manon Cox
Journal:  Vaccine       Date:  2011-08-09       Impact factor: 3.641

2.  Toward more specific and transparent research and development costs: the case of seasonal influenza vaccines.

Authors:  Ayman Chit; Jayson Parker; Scott A Halperin; Manny Papadimitropoulos; Murray Krahn; Paul Grootendorst
Journal:  Vaccine       Date:  2013-07-03       Impact factor: 3.641

3.  Global Vaccine Action Plan. Decade of vaccine collaboration.

Authors: 
Journal:  Vaccine       Date:  2013-04-18       Impact factor: 3.641

4.  A computationally optimized hemagglutinin virus-like particle vaccine elicits broadly reactive antibodies that protect nonhuman primates from H5N1 infection.

Authors:  Brendan M Giles; Corey J Crevar; Donald M Carter; Stephanie J Bissel; Stacey Schultz-Cherry; Clayton A Wiley; Ted M Ross
Journal:  J Infect Dis       Date:  2012-03-23       Impact factor: 5.226

5.  Synthetic generation of influenza vaccine viruses for rapid response to pandemics.

Authors:  Philip R Dormitzer; Pirada Suphaphiphat; Daniel G Gibson; David E Wentworth; Timothy B Stockwell; Mikkel A Algire; Nina Alperovich; Mario Barro; David M Brown; Stewart Craig; Brian M Dattilo; Evgeniya A Denisova; Ivna De Souza; Markus Eickmann; Vivien G Dugan; Annette Ferrari; Raul C Gomila; Liqun Han; Casey Judge; Sarthak Mane; Mikhail Matrosovich; Chuck Merryman; Giuseppe Palladino; Gene A Palmer; Terika Spencer; Thomas Strecker; Heidi Trusheim; Jennifer Uhlendorff; Yingxia Wen; Anthony C Yee; Jayshree Zaveri; Bin Zhou; Stephan Becker; Armen Donabedian; Peter W Mason; John I Glass; Rino Rappuoli; J Craig Venter
Journal:  Sci Transl Med       Date:  2013-05-15       Impact factor: 17.956

6.  Cellular immune correlates of protection against symptomatic pandemic influenza.

Authors:  Saranya Sridhar; Shaima Begom; Alison Bermingham; Katja Hoschler; Walt Adamson; William Carman; Thomas Bean; Wendy Barclay; Jonathan J Deeks; Ajit Lalvani
Journal:  Nat Med       Date:  2013-09-22       Impact factor: 53.440

7.  Biological features of novel avian influenza A (H7N9) virus.

Authors:  Jianfang Zhou; Dayan Wang; Rongbao Gao; Baihui Zhao; Jingdong Song; Xian Qi; Yanjun Zhang; Yonglin Shi; Lei Yang; Wenfei Zhu; Tian Bai; Kun Qin; Yu Lan; Shumei Zou; Junfeng Guo; Jie Dong; Libo Dong; Ye Zhang; Hejiang Wei; Xiaodan Li; Jian Lu; Liqi Liu; Xiang Zhao; Xiyan Li; Weijuan Huang; Leying Wen; Hong Bo; Li Xin; Yongkun Chen; Cuilin Xu; Yuquan Pei; Yue Yang; Xiaodong Zhang; Shiwen Wang; Zijian Feng; Jun Han; Weizhong Yang; George F Gao; Guizhen Wu; Dexin Li; Yu Wang; Yuelong Shu
Journal:  Nature       Date:  2013-07-03       Impact factor: 49.962

Review 8.  Epitope-based approaches to a universal influenza vaccine.

Authors:  Tanya Gottlieb; Tamar Ben-Yedidia
Journal:  J Autoimmun       Date:  2014-08-27       Impact factor: 7.094

9.  Profiling of humoral response to influenza A(H1N1)pdm09 infection and vaccination measured by a protein microarray in persons with and without history of seasonal vaccination.

Authors:  Elisabeth G W Huijskens; Johan Reimerink; Paul G H Mulder; Janko van Beek; Adam Meijer; Erwin de Bruin; Ingrid Friesema; Menno D de Jong; Guus F Rimmelzwaan; Marcel F Peeters; John W A Rossen; Marion Koopmans
Journal:  PLoS One       Date:  2013-01-24       Impact factor: 3.240

10.  Assessment of human immune responses to H7 avian influenza virus of pandemic potential: results from a placebo-controlled, randomized double-blind phase I study of live attenuated H7N3 influenza vaccine.

Authors:  Larisa Rudenko; Irina Kiseleva; Anatoly N Naykhin; Marianna Erofeeva; Marina Stukova; Svetlana Donina; Galina Petukhova; Maria Pisareva; Vera Krivitskaya; Michael Grudinin; Zhanna Buzitskaya; Irina Isakova-Sivak; Svetlana Kuznetsova; Natalie Larionova; Julia Desheva; Irina Dubrovina; Alexandra Nikiforova; John C Victor; Kathy Neuzil; Jorge Flores; Vadim Tsvetnitsky; Oleg Kiselev
Journal:  PLoS One       Date:  2014-02-12       Impact factor: 3.240

View more
  4 in total

1.  Report on the second WHO integrated meeting on development and clinical trials of influenza vaccines that induce broadly protective and long-lasting immune responses: Geneva, Switzerland, 5-7 May 2014.

Authors:  Nancy J Cox; Julian Hickling; Rebecca Jones; Guus F Rimmelzwaan; Linda C Lambert; John Boslego; Larisa Rudenko; Leena Yeolekar; James S Robertson; Joachim Hombach; Justin R Ortiz
Journal:  Vaccine       Date:  2015-10-23       Impact factor: 3.641

2.  Protective immunity against influenza in HLA-A2 transgenic mice by modified vaccinia virus Ankara vectored vaccines containing internal influenza proteins.

Authors:  Giuseppina Di Mario; Ester Sciaraffia; Marzia Facchini; Francesco Gubinelli; Elisa Soprana; Maddalena Panigada; Valentina Bernasconi; Bruno Garulli; Antonio Siccardi; Isabella Donatelli; Maria R Castrucci
Journal:  Pathog Glob Health       Date:  2017-01-12       Impact factor: 2.894

3.  Two Live Attenuated Vaccines against Recent Low⁻and Highly Pathogenic H7N9 Influenza Viruses Are Safe and Immunogenic in Ferrets.

Authors:  Larisa Rudenko; Irina Kiseleva; Elena Krutikova; Ekaterina Stepanova; Irina Isakova-Sivak; Svetlana Donina; Andrey Rekstin; Maria Pisareva; Ekaterina Bazhenova; Tatiana Kotomina; Anastasia Katelnikova; Arman Muzhikyan; Valery Makarov; Erin Grace Sparrow; Guido Torelli
Journal:  Vaccines (Basel)       Date:  2018-11-01

4.  Rationale for vaccination with trivalent or quadrivalent live attenuated influenza vaccines: Protective vaccine efficacy in the ferret model.

Authors:  Larisa Rudenko; Irina Kiseleva; Elena Krutikova; Ekaterina Stepanova; Andrey Rekstin; Svetlana Donina; Maria Pisareva; Elena Grigorieva; Kirill Kryshen; Arman Muzhikyan; Marina Makarova; Erin Grace Sparrow; Guido Torelli; Marie-Paule Kieny
Journal:  PLoS One       Date:  2018-12-03       Impact factor: 3.240

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.